| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Ufenamate targets inflammatory pathways involved in skin diseases. As an anthranilic acid derivative, it inhibits the production of inflammatory mediators, similar to other fenamates. Its anti-inflammatory activity is mediated through the inhibition of prostaglandin synthesis and other inflammatory pathways. The compound's lipophilic nature makes it suitable for topical application, allowing it to penetrate the skin and exert its effects locally.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that ufenamate has anti-inflammatory activity. As an anthranilic acid derivative, it inhibits the production of inflammatory mediators. The compound's photoprotective effect has also been documented. However, detailed in vitro potency data, such as IC₅₀ values for specific activities, are not extensively documented in the available literature.
|
| ln Vivo |
In vivo, ufenamate is used topically for the research of skin diseases, such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliaria, and atopic dermatitis. Its anti-inflammatory activity helps to reduce skin inflammation and irritation. The compound's photoprotective effect may also contribute to its therapeutic benefits. However, comprehensive in vivo efficacy and safety studies are needed to fully evaluate its therapeutic potential.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for ufenamate typically involve measuring its anti-inflammatory activity using cell-free systems. The compound's effects on inflammatory mediators can be assessed using enzyme inhibition assays for COX or LOX. Its photoprotective effect can be assessed by measuring the compound's ability to absorb UV radiation.
|
| Cell Assay |
In vitro cell-based assays for ufenamate use skin cells, such as keratinocytes or fibroblasts, to study its anti-inflammatory and photoprotective effects. Cells are treated with the compound and stimulated with inflammatory stimuli or exposed to UV radiation. Parameters such as inflammatory cytokine production, cell viability, and oxidative stress markers are assessed.
|
| Animal Protocol |
In vivo animal studies for ufenamate would likely employ models of skin inflammation, such as contact dermatitis or eczema. The compound is applied topically, and parameters such as skin inflammation, histopathology of skin tissues, and cytokine levels in skin are assessed. Photoprotective effects can be studied in models of UV-induced skin damage. Pharmacokinetic studies in these models provide information about the compound's absorption through the skin.
|
| ADME/Pharmacokinetics |
Ufenamate has a molecular weight of 337.34 g/mol and a molecular formula of C₁₈H₁₈F₃NO₂. It is a lipophilic fenamate NSAID prodrug. The compound is a liquid with a boiling point of 170°C at 1 mmHg and a flash point of 192°C. It has a LogP of 5.4789. It should be stored under appropriate conditions as recommended by the manufacturer. Detailed pharmacokinetic parameters have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicity profile of ufenamate has been evaluated in the context of its topical use. The compound is generally well-tolerated when applied topically, though skin irritation may occur in sensitive individuals. As an NSAID, it may have systemic effects if absorbed in significant amounts, though topical application minimizes systemic exposure.
|
| Additional Infomation |
Ufenamate acid is an organic molecular entity.
Ufenamate is an anthranilic acid-based anti-inflammatory agent. It is also known as Butyl flufenamate, Flufenamic acid butyl ester, and Fenazol. The compound is a lipophilic fenamate NSAID prodrug optimized for topical dermatological application. Ufenamate can be used for the research of skin diseases, such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliaria, and atopic dermatitis. It has a certain photoprotective effect. Not approved for clinical use; intended for research purposes only. |
| Molecular Formula |
C18H18F3NO2
|
|---|---|
| Molecular Weight |
337.3362
|
| Exact Mass |
337.129
|
| CAS # |
67330-25-0
|
| PubChem CID |
5632
|
| Appearance |
Colorless to light yellow liquid（Density：1.2230 g/cm3）
|
| Density |
1.22g/cm3
|
| Boiling Point |
394.3ºC at 760 mmHg
|
| Flash Point |
192.2ºC
|
| Index of Refraction |
1.536
|
| LogP |
5.478
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
24
|
| Complexity |
400
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1C([H])=C([H])C([H])=C(C=1[H])N([H])C1=C([H])C([H])=C([H])C([H])=C1C(=O)OC([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])(F)F
|
| InChi Key |
JDLSRXWHEBFHNC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H18F3NO2/c1-2-3-11-24-17(23)15-9-4-5-10-16(15)22-14-8-6-7-13(12-14)18(19,20)21/h4-10,12,22H,2-3,11H2,1H3
|
| Chemical Name |
butyl 2-[3-(trifluoromethyl)anilino]benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 44 mg/mL (~130.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9644 mL | 14.8218 mL | 29.6437 mL | |
| 5 mM | 0.5929 mL | 2.9644 mL | 5.9287 mL | |
| 10 mM | 0.2964 mL | 1.4822 mL | 2.9644 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
